18:36:00 EST Tue 17 Nov 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:OTLK - OUTLOOK THERAPEUTICS INC - https://outlooktherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
OTLK - Q1.40.35·0.38961.00.3606-0.0354-8.95,271.81,6205,7450.3875  0.3913  0.352.5375  0.161118:15:45Oct 0915 min RT 2¢

Recent Trades - Last 10 of 5745
Time ETExPriceChangeVolume
18:15:45Q0.375-0.021250
18:14:49Q0.37-0.026604
18:13:35Q0.362-0.034150
18:13:22Q0.3626-0.03344,137
18:13:06Q0.37-0.026300
18:02:34Q0.3742-0.02181,000
17:35:55Q0.3749-0.0211300
17:18:06Q0.37-0.0261,000
17:12:00Q0.375-0.02128
17:10:09Q0.375-0.0211,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-10-09 08:30U:OTLKNews ReleaseOutlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
2026-10-06 09:20U:OTLKNews ReleaseOutlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion
2026-10-01 09:01U:OTLKNews ReleaseOutlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA(TM) (bevacizumab-vikg)
2026-09-11 07:00U:OTLKNews ReleaseOutlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
2026-09-10 09:10U:OTLKNews ReleaseOutlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA(TM) in Virtual Investor CEO Connect Segment
2026-08-27 16:05U:OTLKNews ReleaseOutlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA(TM)
2026-08-27 09:01U:OTLKNews ReleaseOutlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-14 07:15U:OTLKNews ReleaseOutlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA(TM)
2026-08-12 21:45U:OTLKNews ReleaseOutlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
2026-08-12 16:01U:OTLKNews ReleaseOutlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
2026-08-06 08:45U:OTLKNews ReleaseOutlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
2026-07-24 14:40U:OTLKNews ReleaseOutlook Therapeutics Announces LYTENAVA(TM) FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
2026-06-16 08:02U:OTLKNews ReleaseOutlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) as a Treatment for Wet AMD
2026-06-01 08:46U:OTLKNews ReleaseOutlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
2026-05-28 16:00U:OTLKNews ReleaseOutlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2026-05-26 07:00U:OTLKNews ReleaseOutlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
2026-05-15 16:05U:OTLKNews ReleaseOutlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-04-23 16:05U:OTLKNews ReleaseOutlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
2026-04-22 08:30U:OTLKNews ReleaseOutlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2026-04-21 09:05U:OTLKNews ReleaseOutlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)